Aehr Test Secures Record $41 Million Order for AI Chip Testing
Aehr Test Systems' stock surged by 14.55% after crossing above the 5-day SMA, reflecting strong investor interest following a significant announcement.
The company secured a record $41 million follow-on production order from a major hyperscale customer for package-level burn-in testing of custom AI processor ASICs. This order marks the largest in the company's history and indicates robust demand for AI chip validation infrastructure. With this order, Aehr has exceeded its revenue expectations for the second half of fiscal year 2026, booking over $92 million, which was initially projected to be between $60 million and $80 million.
This substantial order not only highlights Aehr's growth potential in the AI sector but also positions the company favorably for future demand across various markets, including silicon photonics and power semiconductors, which could lead to additional bookings before the fiscal year ends.
Trade with 70% Backtested Accuracy
Analyst Views on AEHR
About AEHR
About the author

- Stock Option Exercise: Fariba Danesh, a director at Aehr Test Systems, exercised 8,000 stock options and immediately sold the shares on April 16, 2026, with a transaction value of approximately $661,000, indicating a liquidity-driven decision rather than a bullish outlook on the stock.
- Ownership Changes: Following this transaction, Danesh retains 13,143 shares valued at around $1.09 million, representing a 0.04% ownership stake in the company, highlighting a decline in her direct holdings which may limit future trading capacity.
- Market Performance: The shares were sold at a weighted average price of about $82.63 each, while Aehr's stock has surged 890.8% year-over-year as of April 16, 2026, suggesting she capitalized on significant gains by selling at a peak.
- Order Incentive: On the same day Danesh sold her shares, Aehr announced a $41 million order from an AI hyperscale customer, marking the largest production order in the company's history, which could drive future sales growth despite recent declines in revenue.
- Share Sale Details: On April 16, 2026, Fariba Danesh, a director at Aehr Test Systems, sold 8,000 shares for approximately $661,000, representing 37.8% of her direct holdings, reducing her ownership from 21,143 to 13,143 shares, indicating ongoing portfolio management.
- Price Impact: The sale coincided with Aehr's stock reaching a 52-week high of $91.43, driven by the announcement of a $41 million order from an AI hyperscale customer, marking the largest production order in the company's history, which could enhance future sales growth.
- Market Outlook: Despite a decline in third-quarter sales to $10.3 million from $18.3 million year-over-year, the strong demand in the AI sector supports Aehr's future performance, highlighting its critical role in the semiconductor testing equipment market.
- Investor Caution: While Danesh's sale is not necessarily a negative signal, Aehr's high price-to-sales ratio exceeding 55 suggests elevated stock prices, prompting caution for potential investors, especially as it was not included in the Motley Fool's recommended stocks list.
- Investment Recommendation: Jim Cramer highlighted Vertex Pharmaceuticals' strong stock performance, suggesting that buying early was a good decision, reflecting market confidence in its future growth and potentially attracting more investor interest.
- Industry Challenges: Oddity Tech's performance fell short of expectations, with Cramer admitting he underestimated the industry's complexities, indicating that market confidence in the company may be waning, prompting investors to carefully assess its future potential.
- Risk Assessment: ImmunityBio faces uncertainty, with Cramer emphasizing the need to observe how it resolves current issues, which could impact its stock price trajectory, necessitating vigilance from investors to navigate potential risks.
- Buying Opportunity: Copart is viewed as undervalued, with Cramer suggesting it represents a good buying opportunity, likely attracting investors looking for undervalued stocks and enhancing market interest in the company.
- Aehr Options Volume: Aehr Test Systems has seen an options trading volume of 23,837 contracts today, equating to approximately 2.4 million shares, which represents 69.3% of its average daily trading volume of 3.4 million shares over the past month.
- High Contract Analysis: Notably, the $90 strike call option expiring on April 17, 2026, has traded 1,933 contracts today, representing about 193,300 underlying shares, indicating market expectations for future price increases.
- MongoDB Options Activity: MongoDB Inc recorded an options trading volume of 10,127 contracts, representing approximately 1.0 million shares or 65.6% of its average daily trading volume of 1.5 million shares over the past month, highlighting investor interest in its future performance.
- Put Option Trading: The $230 strike put option expiring on April 17, 2026, has seen 714 contracts traded today, representing about 71,400 underlying shares, reflecting market concerns regarding potential downside risks for MongoDB.
- AMD Stock Surge: AMD shares rose over 7% after Bernstein raised its price target from $235 to $265, with analyst Stacy Rasgon highlighting the company's benefits from strong server CPU demand, which is expected to enhance its market performance further.
- Intel Price Target Increase: Bernstein also lifted Intel's price target from $36 to $60, resulting in a nearly 5% stock increase, reflecting growing market confidence in Intel's future growth potential, which may attract more investor interest.
- Aehr Test Systems Order Boost: Aehr Test Systems announced a $41 million production order from a leading hyperscale AI customer, leading to an 11% stock increase, which not only strengthens the company's market position but also potentially drives future earnings growth.
- PPG Global Price Hike: PPG Industries announced a global price increase of up to 20% across its product portfolio, resulting in about a 5% stock rise, as this move addresses rising raw material and packaging costs, demonstrating the company's proactive strategy in navigating market challenges.
- Contract Expansion: Aehr Test Systems announced a $41 million production expansion order with its largest cloud hyperscaler customer, involving test and package-level burn-in solutions for ASICs used in artificial intelligence applications, which is expected to significantly boost the company's revenue and market share.
- Stock Surge: As of 12:30 p.m. ET, Aehr's stock price rose 13.2%, having peaked at a 24.9% increase earlier in the session, reflecting strong market reaction to the new contract and further solidifying its position in the high-growth AI chip market.
- Year-to-Date Performance: Aehr's stock has surged 311% year-to-date, showcasing the company's robust growth potential amid a backdrop of increasing new contracts, attracting widespread investor interest.
- Market Valuation: With a market capitalization of approximately $2.6 billion, the company is valued at about 53 times this year's expected sales, indicating a high-risk profile; however, the expanding backlog suggests that the company is poised for continued growth.










